HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Alcoholic steatohepatitis — Clinical Guidelines

Overview

Alcoholic steatohepatitis (ASH) is a severe form of alcoholic liver disease characterized by liver inflammation and necrosis due to excessive alcohol consumption combined with fat accumulation in liver cells. It often progresses to fibrosis and cirrhosis if alcohol use continues 1.

Diagnosis

Initial Screening: Ultrasonography for hepatic steatosis 1.

Fibrosis Assessment: Fibrosis-4 (FIB-4) index for risk stratification; further evaluation with vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) test 1.

Liver Enzymes: Elevated levels of ALT, AST, and GGT indicative of liver inflammation 3.

Alcohol Consumption: Quantification of alcohol intake (<140 grams/week for women, <210 grams/week for men) 1.

Management

Alcohol Abstinence: Complete cessation of alcohol consumption, particularly in patients with significant fibrosis 1.

Weight Loss: Targeted weight loss (7-10%) for those with excess weight, often facilitated through dietary modifications like a Mediterranean diet 1.

Lifestyle Modifications: Smoking cessation recommended regardless of fibrosis stage 1.

Pharmacological Interventions: Specific drug classes not detailed in abstracts, but future guidelines may include GLP-1 receptor agonists for metabolic improvements in related conditions 5.

Special Populations

Type 2 Diabetes: Patients with elevated FIB-4 scores should be referred to hepatology for early intervention to prevent unrecognized hepatic decompensation 8.

Comorbidities: Management should consider concurrent conditions like chronic kidney disease, which may influence oxidative stress and antioxidant protection systems 9.

Key Recommendations

Complete Alcohol Abstinence for patients with significant fibrosis to halt disease progression (Evidence: Strong 1).

Implement Non-Invasive Fibrosis Assessment Tools such as FIB-4, vibration-controlled transient elastography, or ELF test for risk stratification (Evidence: Moderate 1 3).

Promote Lifestyle Modifications including smoking cessation and adherence to a Mediterranean diet with targeted weight loss (Evidence: Moderate 1).

Refer Patients with Elevated FIB-4 Scores in Type 2 Diabetes to hepatology for further evaluation and management (Evidence: Moderate 8).

References

1 Diaz LA, Arab JP, Idalsoaga F, Perelli J, Vega J, Dirchwolf M et al.. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group. Annals of hepatology 2025. link 2 Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A et al.. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology 2025. link 3 Kim Y, Rydqvist P, Ramezani T, Haas JS, Bantel H, Buggisch P et al.. Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel. Liver international : official journal of the International Association for the Study of the Liver 2025. link 4 Chan KE, Ong EYH, Chung CH, Ong CEY, Koh B, Tan DJH et al.. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024. link 5 Fang L, Li J, Zeng H, Liu J. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis. Primary care diabetes 2024. link 6 Dalal N, Catalli L, Miller SA, Madan S, Tan R, Agudelo E et al.. BRIDGE to liver health: implementation of a group telehealth psychoeducational program through shared medical appointments for MASLD management. BMC public health 2024. link 7 Noureddin M, Goodman Z, Tai D, Chng ELK, Ren Y, Boudes P et al.. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. Alimentary pharmacology & therapeutics 2023. link 8 Dunn W, Song X, Koestler D, Grdinovac K, Al-Hihi E, Chen J et al.. Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation. Journal of gastroenterology and hepatology 2022. link 9 Khukhlina O, Antoniv A, Kanovska L, Matushchak M, Vivsyannuk V. INTENSITY OF THE ANTIOXIDANT PROTECTION SYSTEM AND OXIDATIVE STRESS FACTORS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS DEPENDING ON THE FORM OF CHRONIC KIDNEY DISEASE. Georgian medical news 2018. link 10 Scheen AJ, Luyckx FH. Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists. Acta clinica Belgica 2003. link

Alcoholic steatohepatitis